|Secondary Protocol No.
||MT2012-01 : A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies BMT CTN PROTOCOL 1101
||The prmary objective is to compare progression-free survival at 2 years post-randomization between patients who receive unrelated double cord blood unit transplantation versus HLA-haploidentical related bone marrow transplantation.
||Patients will be randomized to receive either a donor umbilical cord blood or related HLA-haploidentical bone marrow transplantation.
||This study is a multi-center trial of reduced intensity conditioning followed by transplantation of two unrelated cord blood units with calcineurin inhibitor and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) versus HLA-haploidentical related bone marrow with post-transplant cyclophosphamide, calcineurin inhibitor and MMF for GVHD prophylaxis.
||Patient must have 1) acute lymphoblastic leukemia/lymphoma, acute myelogenous leukemia, or Burkitt's lymphoma in remission; 2) lymphoma, including marginal zone lymphoma, follicular lymphoma, or chemotherapy-sensitive large-cell, Hodgkin or mantle cell lymphoma.
|Applicable Disease Sites
||Blood and Marrow Transplant
||CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
Total Body irradiation (TBI)
||Masonic Cancer Center
||Patient must be between 18 and 70 years of age and with two partially HLA-matched UCB units. Must have adequate organ function. Anyone who has received an autologous hematopoietic stem cell transplant less than 6 months prior to enrollment or prior allogeneic HSCT is not eligible. Women who are pregnant or nursing are not eligible. A signed informed consent and HIPAA authorization are required.